Vibsanin B preferentially targets HSP90β, inhibits interstitial leukocyte migration, and ameliorates experimental autoimmune encephalomyelitis

Journal of Immunology

Volumn 194, Issue 9, 2015, Pages 4489-4497

  Ye, Bai Xin ^a   Deng, Xu ^b   Shao, Li Dong ^b   Lu, Ying ^a   Xiao, Run ^a   Liu, Yi Jie ^a   Jin, Yi ^a   Xie, Yin Yin ^a   Zhao, Yan ^a   Luo, Liu Fei ^a   Ma, Shun ^c   Gao, Ming ^d   Zhang, Lian Ru ^c   He, Juan ^b   Zhang, Wei Na ^a   Chen, Yi ^a   Xia, Cheng Feng ^b   Deng, Min ^a   Liu, Ting Xi ^a   Zhao, Qin Shi ^a,b   Chen, Sai Juan ^a   Chen, Zhu ^a   more..

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b KUNMING INSTITUTE OF BOTANY   (China)

^c XIAMEN UNIVERSITY   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DITERPENOID; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 90 BETA; PROTEIN KINASE B; UNCLASSIFIED DRUG; VIBSANIN B; DITERPENE; HEAT SHOCK PROTEIN 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG TARGETING; EMBRYO; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIBURNUM; VIBURNUM ODORATISSIMUM; ZEBRA FISH; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL MOTION; CENTRAL NERVOUS SYSTEM; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOLOGY; LEUKOCYTE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; SPINAL CORD;

ANIMALS; CELL LINE; CELL MOVEMENT; CENTRAL NERVOUS SYSTEM; DITERPENES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LEUKOCYTES; MICE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SPINAL CORD; ZEBRAFISH;

EID: 84928482508     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402798     Document Type: Article

References (46)

1. Friedl, P., and B. Weigelin. 2008. Interstitial leukocyte migration and immune function. Nat. Immunol. 9: 960-969.
2. Nathan, C., and A. Ding. 2010. Nonresolving inflammation. Cell 140: 871-882.
3. Mackay, C. R. 2008. Moving targets: cell migration inhibitors as new anti-inflammatory therapies. Nat. Immunol. 9: 988-998.
4. Ajami, B., J. L. Bennett, C. Krieger, K. M. McNagny, and F. M. Rossi. 2011. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat. Neurosci. 14: 1142-1149.
5. Basu, S., and C. Sachidanandan. 2013. Zebrafish: a multifaceted tool for chemical biologists. Chem. Rev. 113: 7952-7980.
6. Zon, L. I., and R. T. Peterson. 2005. In vivo drug discovery in the zebrafish. Nat. Rev. Drug Discov. 4: 35-44.
7. Lieschke, G. J., and P. D. Currie. 2007. Animal models of human disease: zebrafish swim into view. Nat. Rev. Genet. 8: 353-367.
8. Renshaw, S. A., C. A. Loynes, D. M. Trushell, S. Elworthy, P. W. Ingham, and M. K. Whyte. 2006. A transgenic zebrafish model of neutrophilic inflammation. Blood 108: 3976-3978.
9. Zhang, Y., X. T. Bai, K. Y. Zhu, Y. Jin, M. Deng, H. Y. Le, Y. F. Fu, Y. Chen, J. Zhu, A. T. Look, et al. 2008. In vivo interstitial migration of primitive macrophages mediated by JNK-matrix metalloproteinase 13 signaling in response to acute injury. J. Immunol. 181: 2155-2164.
10. Niethammer, P., C. Grabher, A. T. Look, and T. J. Mitchison. 2009. A tissue-scale gradient of hydrogen peroxide mediates rapid wound detection in zebrafish. Nature 459: 996-999.
11. Yan, B., P. Han, L. Pan, W. Lu, J. Xiong, M. Zhang, W. Zhang, L. Li, and Z. Wen. 2014. IL-1β and reactive oxygen species differentially regulate neutrophil directional migration and basal random motility in a zebrafish injury-induced inflammation model. J. Immunol. 192: 5998-6008.
12. Liu, Y. J., H. B. Fan, Y. Jin, C. G. Ren, X. E. Jia, L. Wang, Y. Chen, M. Dong, K. Y. Zhu, Z. W. Dong, et al. 2013. Cannabinoid receptor 2 suppresses leukocyte inflammatory migration by modulating the JNK/c-Jun/Alox5 pathway. J. Biol. Chem. 288: 13551-13562.
13. Robertson, A. L., G. R. Holmes, A. N. Bojarczuk, J. Burgon, C. A. Loynes, M. Chimen, A. K. Sawtell, B. Hamza, J. Willson, S. R. Walmsley, et al. 2014. A zebrafish compound screen reveals modulation of neutrophil reverse migration as an anti-inflammatory mechanism. Sci. Transl. Med. 6: 225ra29. doi:10.1126/scitranslmed.3007672.
14. Taipale, M., D. F. Jarosz, and S. Lindquist. 2010. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat. Rev. Mol. Cell Biol. 11: 515-528.
15. Hartmann, S., N. Günther, M. Biehl, A. Katzer, S. Kuger, E. Worschech, V. L. Sukhorukov, G. Krohne, H. Zimmermann, M. Flentje, and C. S. Djuzenova. 2013. Hsp90 inhibition by NVP-AUY922 and NVP-BEP800 decreases migration and invasion of irradiated normoxic and hypoxic tumor cell lines. Cancer Lett. 331: 200-210.
16. Miao, R. Q., J. Fontana, D. Fulton, M. I. Lin, K. D. Harrison, and W. C. Sessa. 2008. Dominant-negative Hsp90 reduces VEGF-stimulated nitric oxide release and migration in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 28: 105-111.
17. Taiyab, A., and ChM. Rao. 2011. HSP90 modulates actin dynamics: inhibition of HSP90 leads to decreased cell motility and impairs invasion. Biochim. Biophys. Acta 1813: 213-221.
18. Madsen, C. D., and E. Sahai. 2010. Cancer dissemination - lessons from leukocytes. Dev. Cell 19: 13-26.
19. Yun, T. J., E. K. Harning, K. Giza, D. Rabah, P. Li, J. W. Arndt, D. Luchetti, M. A. Biamonte, J. Shi, K. Lundgren, et al. 2011. EC144, a synthetic inhibitor of heat shock protein 90, blocks innate and adaptive immune responses in models of inflammation and autoimmunity. J. Immunol. 186: 563-575.
20. Waza, M., H. Adachi, M. Katsuno, M. Minamiyama, C. Sang, F. Tanaka, A. Inukai, M. Doyu, and G. Sobue. 2005. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat. Med. 11: 1088-1095.
21. Fukuyama, Y., M. Kubo, T. Esumi, K. Harada, and H. Hioki. 2010. Chemistry and biological activities of vibsane-type diterpenoids. Heterocycles 81: 1571-1602.
22. Fang, H. T., B. Zhang, X. F. Pan, L. Gao, T. Zhen, H. X. Zhao, L. Ma, J. Xie, Z. Liu, X. J. Yu, et al. 2012. Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells. Proc. Natl. Acad. Sci. USA 109: 2521-2526.
23. Wei, W., D. Wang, J. Shi, Y. Xiang, Y. Zhang, S. Liu, Y. Liu, and D. Zheng. 2010. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces chemotactic migration of monocytes via a death receptor 4-mediated RhoGTPase pathway. Mol. Immunol. 47: 2475-2484.
24. Millius, A., and O. D. Weiner. 2010. Manipulation of neutrophil-like HL-60 cells for the study of directed cell migration. Methods Mol. Biol. 591: 147-158.
25. Liu, C. X., Q. Q. Yin, H. C. Zhou, Y. L. Wu, J. X. Pu, L. Xia, W. Liu, X. Huang, T. Jiang, M. X. Wu, et al. 2012. Adenanthin targets peroxiredoxin I and II to induce differentiation of leukemic cells. Nat. Chem. Biol. 8: 486-493.
26. 3. Blood 121: 700-706.
27. Yeyati, P. L., R. M. Bancewicz, J. Maule, and V. van Heyningen. 2007. Hsp90 selectively modulates phenotype in vertebrate development. PLoS Genet. 3: e43. Available at: http://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.0030043#pgen-0030043-g009.
28. Lu, Y., B. Chen, J. H. Song, T. Zhen, B. Y. Wang, X. Li, P. Liu, X. Yang, Q. L. Zhang, X. D. Xi, et al. 2013. Eriocalyxin B ameliorates experimental autoimmune encephalomyelitis by suppressing Th1 and Th17 cells. Proc. Natl. Acad. Sci. USA 110: 2258-2263.
29. Stromnes, I. M., and J. M. Goverman. 2006. Active induction of experimental allergic encephalomyelitis. Nat. Protoc. 1: 1810-1819.
30. Oyebamiji, A. I., T. M. Finlay, R. M. Hough, V. Hoghooghi, E. M. Lim, C. H. Wong, and S. S. Ousman. 2013. Characterization of migration parameters on peripheral and central nervous system T cells following treatment of experimental allergic encephalomyelitis with CRYAB. J. Neuroimmunol. 259: 66-74.
31. Kimura, H., H. Yukitake, Y. Tajima, H. Suzuki, T. Chikatsu, S. Morimoto, Y. Funabashi, H. Omae, T. Ito, Y. Yoneda, and M. Takizawa. 2010. ITZ-1, a client-selective Hsp90 inhibitor, efficiently induces heat shock factor 1 activation. Chem. Biol. 17: 18-27.
32. Yoo, S. K., Q. Deng, P. J. Cavnar, Y. I. Wu, K. M. Hahn, and A. Huttenlocher. 2010. Differential regulation of protrusion and polarity by PI3K during neutrophil motility in live zebrafish. Dev. Cell 18: 226-236.
33. Dello Russo, C., P. E. Polak, P. R. Mercado, A. Spagnolo, A. Sharp, P. Murphy, A. Kamal, F. J. Burrows, L. C. Fritz, and D. L. Feinstein. 2006. The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis. J. Neurochem. 99: 1351-1362.
34. Dogan, R. N., N. Long, E. Forde, K. Dennis, A. P. Kohm, S. D. Miller, and W. J. Karpus. 2011. CCL22 regulates experimental autoimmune encephalomyelitis by controlling inflammatory macrophage accumulation and effector function. J. Leukoc. Biol. 89: 93-104.
35. Paterson, I., and E. A. Anderson. 2005. Chemistry. The renaissance of natural products as drug candidates. Science 310: 451-453.
36. Li, J. W. H., and J. C. Vederas. 2009. Drug discovery and natural products: end of an era or an endless frontier? Science 325: 161-165.
37. Mak, J. Y. W., and C. M. Williams. 2012. Key achievements in the total synthesis of vibsane-type diterpenoids. Nat. Prod. Rep. 29: 440-448.
38. Wang, L.-Q., Y.-G. Chen, J.-J. Xu, Y. Liu, X.-M. Li, and Y. Zhao. 2008. Compounds from Viburnum species and their biological activities. Chem. Biodivers. 5: 1879-1899.
39. Shao, L.-D., J. Xu, X. Gao, J. He, Y. Zhao, L.-Y. Peng, H.-R. Luo, C. Xia, and Q.-S. Zhao. 2014. Synthesis and neurite outgrowth promoting activity of vibsanin B derivatives. Tetrahedron Lett. 55: 3414-3417.
40. Cravatt, B. F., A. T. Wright, and J. W. Kozarich. 2008. Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. Annu. Rev. Biochem. 77: 383-414.
41. Trepel, J., M. Mollapour, G. Giaccone, and L. Neckers. 2010. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 10: 537-549.
42. Eustace, B. K., T. Sakurai, J. K. Stewart, D. Yimlamai, C. Unger, C. Zehetmeier, B. Lain, C. Torella, S. W. Henning, G. Beste, et al. 2004. Functional proteomic screens reveal an essential extracellular role for hsp90α in cancer cell invasiveness. Nat. Cell Biol. 6: 507-514.
43. Donnelly, A., and B. S. Blagg. 2008. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr. Med. Chem. 15: 2702-2717.
44. Sato, S., N. Fujita, and T. Tsuruo. 2000. Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl. Acad. Sci. USA 97: 10832-10837.
45. Thompson, A. J., A. T. Toosy, and O. Ciccarelli. 2010. Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol. 9: 1182-1199.
46. Conway, D., and J. A. Cohen. 2010. Combination therapy in multiple sclerosis. Lancet Neurol. 9: 299-308.